This article was medically reviewed by Carolyn Swenson, MD, an assistant professor of obstetrics and gynecology and member of the Prevention Medical Review Board, on July 3, 2019. You’re doing your ...

Elinzanetant vs placebo reduced hot flashes and night sweats by 74% vs 47% at 12 weeks in postmenopausal women. The benefits lasted 52 weeks with no major safety concerns reported. Researchers ran a ...

The Food and Drug Administration has approved a new pill for menopausal women to treat hot flashes and night sweats. Drug manufacturer Bayer created the first-ever FDA-approved non-hormonal medication ...

Big news in the menopause world: The Food and Drug Administration has just approved the drug elinzanetant as a non-hormonal treatment for hot flashes. The medication, which will be marketed under the ...

The Food and Drug Administration has approved a new nonhormonal menopause medication to treat hot flashes. Elinzanetant, which was given the green light Friday under the brand name Lynkuet, belongs to ...

(CNN) — The US Food and Drug Administration has approved another once-a-day pill that works without hormones to treat moderate to severe hot flashes in menopausal women, drugmaker Bayer said Friday.

These results suggest that oxybutynin may offer a practical and effective option for managing ADT-associated hot flashes in ...

A medication commonly used to treat overactive bladder significantly reduced hot flashes in men receiving hormone therapy for ...

Researchers report that oxybutynin outperformed placebo in lowering daily hot flash frequency and intensity among men on hormone therapy for prostate cancer. The drug also enhanced sleep, social ...